Avid Bioservices Inc (NASDAQ:CDMO) Expected to Announce Earnings of -$0.03 Per Share

Share on StockTwits

Equities research analysts expect that Avid Bioservices Inc (NASDAQ:CDMO) will post earnings per share of ($0.03) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Avid Bioservices’ earnings, with estimates ranging from ($0.03) to ($0.02). Avid Bioservices posted earnings of ($0.06) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 50%. The company is expected to report its next quarterly earnings results on Monday, September 9th.

According to Zacks, analysts expect that Avid Bioservices will report full-year earnings of ($0.07) per share for the current year, with EPS estimates ranging from ($0.12) to ($0.03). For the next financial year, analysts anticipate that the company will report earnings of $0.12 per share, with EPS estimates ranging from $0.04 to $0.20. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Avid Bioservices.

Avid Bioservices (NASDAQ:CDMO) last issued its quarterly earnings results on Thursday, June 27th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.01. The business had revenue of $17.06 million for the quarter, compared to analysts’ expectations of $15.53 million. Avid Bioservices had a negative net margin of 7.86% and a negative return on equity of 9.29%.

Several analysts recently weighed in on CDMO shares. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a report on Tuesday. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. HC Wainwright set a $73.00 price target on Uniqure and gave the company a “buy” rating in a research report on Monday, July 8th. TheStreet raised South Jersey Industries from a “c+” rating to a “b-” rating in a research report on Tuesday. Finally, Janney Montgomery Scott lowered Unitil from a “buy” rating to a “neutral” rating and set a $59.79 price target on the stock. in a research report on Friday, June 28th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Avid Bioservices currently has a consensus rating of “Buy” and an average price target of $8.58.

Shares of CDMO traded up $0.04 during mid-day trading on Friday, hitting $6.09. 417,439 shares of the company’s stock were exchanged, compared to its average volume of 914,611. The company has a market capitalization of $339.63 million, a P/E ratio of -35.82 and a beta of 2.88. Avid Bioservices has a fifty-two week low of $3.37 and a fifty-two week high of $8.44. The company has a 50-day moving average of $4.51.

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC grew its stake in shares of Avid Bioservices by 5.5% in the fourth quarter. Geode Capital Management LLC now owns 527,772 shares of the biopharmaceutical company’s stock worth $2,163,000 after purchasing an additional 27,685 shares in the last quarter. Roubaix Capital LLC purchased a new stake in Avid Bioservices in the 1st quarter worth about $2,077,000. Bank of New York Mellon Corp lifted its stake in Avid Bioservices by 10.0% in the 4th quarter. Bank of New York Mellon Corp now owns 170,342 shares of the biopharmaceutical company’s stock worth $699,000 after acquiring an additional 15,459 shares in the last quarter. Harborview Advisors LLC purchased a new stake in Avid Bioservices in the 1st quarter worth about $52,000. Finally, Jane Street Group LLC purchased a new stake in Avid Bioservices in the 4th quarter worth about $82,000. 38.62% of the stock is currently owned by hedge funds and other institutional investors.

Avid Bioservices Company Profile

Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Read More: What is the Rule of 72?

Get a free copy of the Zacks research report on Avid Bioservices (CDMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Avid Bioservices (NASDAQ:CDMO)

Receive News & Ratings for Avid Bioservices Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avid Bioservices and related companies with MarketBeat.com's FREE daily email newsletter.